Literature DB >> 16173960

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network.

Markus Tiemann1, Carsten Schrader, Wolfram Klapper, Martin H Dreyling, Elias Campo, Andrew Norton, Francoise Berger, Philip Kluin, German Ott, Stephano Pileri, Ennio Pedrinis, Alfred C Feller, Hartmut Merz, Dirk Janssen, Martin L Hansmann, Han Krieken, Peter Möller, Harald Stein, Michael Unterhalt, Wolfgang Hiddemann, Reza Parwaresch.   

Abstract

Mantle cell lymphoma (MCL) is a distinct lymphoma subtype with a particularly poor clinical outcome. The clinical relevance of the morphological characteristics of these tumours remains uncertain. The European MCL Network reviewed 304 cases of MCL to determine the prognostic significance of histopathological characteristics. Cytomorphological subtypes, growth pattern and markers of proliferation (mitotic and Ki-67 indices) were analysed. In addition to the known cytological subtypes, classical (87.5%), small cell (3.6%), pleomorphic (5.9%) and blastic (2.6%), we identified new pleomorphic subgroups with mixtures of cells (classical + pleomorphic type; 1.6%) or transitions (classical/pleomorphic type; 1.6%), which, however, did not differ significantly in overall survival time. Exactly 80.5% of cases displayed a diffuse growth pattern, whereas 19.5% of cases had a nodular growth pattern, which was associated with a slightly more favourable prognosis. A high proliferation rate (mitotic or Ki-67 indices) was associated with shorter overall survival. Cut-off levels were defined that allowed three subgroups with different proliferation rates to be discriminated, which showed significantly different clinical outcomes (P < 0.0001). Based on this large clinicopathological study of prospective clinical trials, multivariate analysis confirmed the central prognostic role of cell proliferation and its superiority to all other histomorphological and clinical criteria.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16173960     DOI: 10.1111/j.1365-2141.2005.05716.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  72 in total

1.  Mantle-cell lymphoma in barrett esophagus.

Authors:  Cesar V Reyes
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-05

2.  A novel quantitative PCR of proliferation markers (Ki-67, topoisomerase IIalpha, and TPX2): an immunohistochemical correlation, testing, and optimizing for mantle cell lymphoma.

Authors:  Helena Brizova; Marketa Kalinova; Lenka Krskova; Marcela Mrhalova; Roman Kodet
Journal:  Virchows Arch       Date:  2010-04-24       Impact factor: 4.064

3.  The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.

Authors:  Julia Slotta-Huspenina; Ina Koch; Laurence de Leval; Gisela Keller; Margit Klier; Karin Bink; Marcus Kremer; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

4.  Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement.

Authors:  Masaya Iwamuro; Hiroyuki Okada; Yoshiro Kawahara; Katsuji Shinagawa; Toshiaki Morito; Tadashi Yoshino; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

Review 5.  Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

Authors:  Stephen E Spurgeon; Brian G Till; Peter Martin; Andre H Goy; Martin P Dreyling; Ajay K Gopal; Michael LeBlanc; John P Leonard; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; Brad S Kahl; Mitchell R Smith
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

6.  Blastic Transformation of a Mantle Cell Lymphoma Presenting as an Enlarging Unilateral Orbital Mass.

Authors:  Matthew A De Niear; John P Greer; Adam Seegmiller; Louise A Mawn
Journal:  Ocul Oncol Pathol       Date:  2018-11-16

Review 7.  Mantle cell lymphoma: observation to transplantation.

Authors:  Babak Rajabi; John W Sweetenham
Journal:  Ther Adv Hematol       Date:  2015-02

Review 8.  Mantle cell lymphoma: are current therapies changing the course of disease?

Authors:  Christian Geisler
Journal:  Curr Oncol Rep       Date:  2009-09       Impact factor: 5.075

Review 9.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

10.  Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.

Authors:  Brian G Till; Hongli Li; Steven H Bernstein; Richard I Fisher; W Richard Burack; Lisa M Rimsza; Justin D Floyd; Marco A DaSilva; Dennis F Moore; Olga Pozdnyakova; Sonali M Smith; Michael LeBlanc; Jonathan W Friedberg
Journal:  Br J Haematol       Date:  2015-10-22       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.